Sickle Cell Disease Clinical Trial Pipeline Highlights 2019 – Global Forecast to 2024 by Clinical Trial Stages, Drug Mechanism Classes, Company – ResearchAndMarkets.com

June 13, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global
Sickle Cell Disease Clinical Trial Pipeline Highlights – 2019”

report has been added to ResearchAndMarkets.com’s
offering.

Sickle Cell Disease Pipeline Highlights – 2019, provides most up-to-date
information on key pipeline products in the global Sickle Cell Disease
market. It covers emerging therapies for Sickle Cell Disease in active
clinical development stages including early and late stage clinical
trials. The pipeline data presented in this report helps executives in
tracking competition, identifying partners, evaluating opportunities,
formulating business development strategies, and executing in-licensing
and out-licensing deals.

Clinical Trial Stages:

The report provides Sickle Cell Disease pipeline products by clinical
trial stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Sickle Cell Disease pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Sickle Cell Disease pipeline products by the company.

Short-term Launch Highlights:

Find out which Sickle Cell Disease pipeline products will be launched in
the US and Ex-US to 2024.

Key Topics Covered:

1. Sickle Cell Disease Pipeline by Stages

2. Sickle Cell Disease Phase 3 Clinical Trial Insights

3. Sickle Cell Disease Phase 2 Clinical Trial Insights

4. Sickle Cell Disease Phase 1 Clinical Trial Insights

5. Sickle Cell Disease Preclinical Research Insights

6. Sickle Cell Disease Discovery Stage Insights

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ysssbc

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials
, Hematological
Drugs